Farmakogenomik (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Farmakogenomik" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

20nih.gov

4^th place

13^th place

18doi.org

2^nd place

4^th place

9web.archive.org

1^st place

3archive.org

6^th place

2^nd place

2fda.gov

447^th place

792^nd place

1unc.edu

1,538^th place

1,848^th place

1uptodate.com

3,771^st place

8,592^nd place

1worldcat.org

5^th place

7^th place

1genetics.edu.au

low place

1ugm.ac.id

8,205^th place

97^th place

1cpicpgx.org

low place

1psychiatrictimes.com

9,815^th place

low place

archive.org

Johnson JA (November 2003). "Pharmacogenetics: potential for individualized drug therapy through genetics". Trends in Genetics. 19 (11): 660–666. doi:10.1016/j.tig.2003.09.008. PMID 14585618.
Johnson JA (November 2003). "Pharmacogenetics: potential for individualized drug therapy through genetics". Trends in Genetics. 19 (11): 660–666. doi:10.1016/j.tig.2003.09.008. PMID 14585618.
Cohen N (November 2008). Pharmacogenomics and Personalized Medicine (Methods in Pharmacology and Toxicology). Totowa, NJ: Humana Press. hlm. 6. ISBN 978-1934115046.

cpicpgx.org

"Clinical Pharmacogenetics Implementation Consortium". cpicpgx.org (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 2023-07-01. Diakses tanggal 2022-12-13.

doi.org

Johnson JA (November 2003). "Pharmacogenetics: potential for individualized drug therapy through genetics". Trends in Genetics. 19 (11): 660–666. doi:10.1016/j.tig.2003.09.008. PMID 14585618.
Holtzman, Neil A.; Marteau, Theresa M. (2000-07-13). "Will Genetics Revolutionize Medicine?". New England Journal of Medicine. 343 (2): 141–144. doi:10.1056/nejm200007133430213. ISSN 0028-4793. Diarsipkan dari versi asli tanggal 2023-07-18. Diakses tanggal 2023-03-04.
Becquemont L (June 2009). "Pharmacogenomics of adverse drug reactions: practical applications and perspectives". Pharmacogenomics. 10 (6): 961–969. doi:10.2217/pgs.09.37. PMID 19530963.
Hauser AS, Chavali S, Masuho I, Jahn LJ, Martemyanov KA, Gloriam DE, Babu MM (January 2018). "Pharmacogenomics of GPCR Drug Targets". Cell. 172 (1–2): 41–54.e19. doi:10.1016/j.cell.2017.11.033. PMC 5766829 . PMID 29249361.
Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, et al. (August 2010). "Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice". Pharmacogenomics. 11 (8): 1149–1167. doi:10.2217/pgs.10.97. PMID 20712531.
Pirmohamed M (October 2001). "Pharmacogenetics and pharmacogenomics". British Journal of Clinical Pharmacology. 52 (4): 345–347. doi:10.1046/j.0306-5251.2001.01498.x. PMC 2014592 . PMID 11678777.
Evans DA, Clarke CA (September 1961). "Pharmacogenetics". British Medical Bulletin. 17 (3): 234–240. doi:10.1093/oxfordjournals.bmb.a069915. PMID 13697554.
Johnson JA (November 2003). "Pharmacogenetics: potential for individualized drug therapy through genetics". Trends in Genetics. 19 (11): 660–666. doi:10.1016/j.tig.2003.09.008. PMID 14585618.
Kalow W (2006). "Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine". The Pharmacogenomics Journal. 6 (3): 162–165. doi:10.1038/sj.tpj.6500361. PMID 16415920.
Motulsky AG, Qi M (February 2006). "Pharmacogenetics, pharmacogenomics and ecogenetics". Journal of Zhejiang University. Science. B. 7 (2): 169–170. doi:10.1631/jzus.2006.B0169. PMC 1363768 . PMID 16421980.
Shin J, Kayser SR, Langaee TY (April 2009). "Pharmacogenetics: from discovery to patient care". American Journal of Health-System Pharmacy. 66 (7): 625–637. doi:10.2146/ajhp080170. PMID 19299369.
Klotz U (2007). "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications". Clinical Pharmacokinetics. 46 (4): 271–279. doi:10.2165/00003088-200746040-00001. PMID 17375979.
Nigam SK (January 2015). "What do drug transporters really do?". Nature Reviews. Drug Discovery. 14 (1): 29–44. doi:10.1038/nrd4461. PMC 4750486 . PMID 25475361.
Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, et al. (April 2012). "Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin". Journal of Clinical Pharmacy and Therapeutics. 37 (2): 232–236. doi:10.1111/j.1365-2710.2011.01262.x. PMID 21507031.
Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C (October 2010). "Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?". Clinical Colorectal Cancer. 9 (4): 224–228. doi:10.3816/CCC.2010.n.033. PMID 20920994.
Foster A, Wang Z, Usman M, Stirewalt E, Buckley P (December 2007). "Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians". Neuropsychiatric Disease and Treatment. 3 (6): 965–973. doi:10.2147/ndt.s1752. PMC 2656342 . PMID 19300635.
Bale BF, Doneen AL, Vigerust DJ (2018). "Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping". Frontiers in Cardiovascular Medicine. 5: 141. doi:10.3389/fcvm.2018.00141 . PMC 6198642 . PMID 30386783.

dx.doi.org

Holtzman, Neil A.; Marteau, Theresa M. (2000-07-13). "Will Genetics Revolutionize Medicine?". New England Journal of Medicine. 343 (2): 141–144. doi:10.1056/nejm200007133430213. ISSN 0028-4793. Diarsipkan dari versi asli tanggal 2023-07-18. Diakses tanggal 2023-03-04.

fda.gov

"Guidance for Industry Pharmacogenomic Data Submissions" (PDF). U.S. Food and Drug Administration. March 2005. Diarsipkan (PDF) dari versi asli tanggal 2016-10-06. Diakses tanggal 2008-08-27.
U.S. Food and Drug Administration (FDA). "Table of Pharmacogenomic Biomarkers in Drug Labels". Food and Drug Administration. Diarsipkan dari versi asli tanggal 2017-08-22. Diakses tanggal 2014-09-03.

genetics.edu.au

"Center for Genetics Education". ^{[pranala nonaktif]}

nih.gov

ncbi.nlm.nih.gov

Johnson JA (November 2003). "Pharmacogenetics: potential for individualized drug therapy through genetics". Trends in Genetics. 19 (11): 660–666. doi:10.1016/j.tig.2003.09.008. PMID 14585618.
Becquemont L (June 2009). "Pharmacogenomics of adverse drug reactions: practical applications and perspectives". Pharmacogenomics. 10 (6): 961–969. doi:10.2217/pgs.09.37. PMID 19530963.
Sheffield LJ, Phillimore HE (May 2009). "Clinical use of pharmacogenomic tests in 2009". The Clinical Biochemist. Reviews. 30 (2): 55–65. PMC 2702214 . PMID 19565025.
Hauser AS, Chavali S, Masuho I, Jahn LJ, Martemyanov KA, Gloriam DE, Babu MM (January 2018). "Pharmacogenomics of GPCR Drug Targets". Cell. 172 (1–2): 41–54.e19. doi:10.1016/j.cell.2017.11.033. PMC 5766829 . PMID 29249361.
Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, et al. (August 2010). "Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice". Pharmacogenomics. 11 (8): 1149–1167. doi:10.2217/pgs.10.97. PMID 20712531.
Pirmohamed M (October 2001). "Pharmacogenetics and pharmacogenomics". British Journal of Clinical Pharmacology. 52 (4): 345–347. doi:10.1046/j.0306-5251.2001.01498.x. PMC 2014592 . PMID 11678777.
Prasad K (January 2009). "Role of regulatory agencies in translating pharmacogenetics to the clinics". Clinical Cases in Mineral and Bone Metabolism. 6 (1): 29–34. PMC 2781218 . PMID 22461095.
Evans DA, Clarke CA (September 1961). "Pharmacogenetics". British Medical Bulletin. 17 (3): 234–240. doi:10.1093/oxfordjournals.bmb.a069915. PMID 13697554.
Johnson JA (November 2003). "Pharmacogenetics: potential for individualized drug therapy through genetics". Trends in Genetics. 19 (11): 660–666. doi:10.1016/j.tig.2003.09.008. PMID 14585618.
Kalow W (2006). "Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine". The Pharmacogenomics Journal. 6 (3): 162–165. doi:10.1038/sj.tpj.6500361. PMID 16415920.
Motulsky AG, Qi M (February 2006). "Pharmacogenetics, pharmacogenomics and ecogenetics". Journal of Zhejiang University. Science. B. 7 (2): 169–170. doi:10.1631/jzus.2006.B0169. PMC 1363768 . PMID 16421980.
Sheffield LJ, Phillimore HE (May 2009). "Clinical use of pharmacogenomic tests in 2009". The Clinical Biochemist. Reviews. 30 (2): 55–65. PMC 2702214 . PMID 19565025.
Shin J, Kayser SR, Langaee TY (April 2009). "Pharmacogenetics: from discovery to patient care". American Journal of Health-System Pharmacy. 66 (7): 625–637. doi:10.2146/ajhp080170. PMID 19299369.
Klotz U (2007). "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications". Clinical Pharmacokinetics. 46 (4): 271–279. doi:10.2165/00003088-200746040-00001. PMID 17375979.
Nigam SK (January 2015). "What do drug transporters really do?". Nature Reviews. Drug Discovery. 14 (1): 29–44. doi:10.1038/nrd4461. PMC 4750486 . PMID 25475361.
Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, et al. (April 2012). "Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin". Journal of Clinical Pharmacy and Therapeutics. 37 (2): 232–236. doi:10.1111/j.1365-2710.2011.01262.x. PMID 21507031.
Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C (October 2010). "Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?". Clinical Colorectal Cancer. 9 (4): 224–228. doi:10.3816/CCC.2010.n.033. PMID 20920994.
Foster A, Wang Z, Usman M, Stirewalt E, Buckley P (December 2007). "Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians". Neuropsychiatric Disease and Treatment. 3 (6): 965–973. doi:10.2147/ndt.s1752. PMC 2656342 . PMID 19300635.
Dean L (2012). "Clopidogrel Therapy and CYP2C19 Genotype". Dalam Pratt VM, McLeod HL, Rubinstein WS, et al. Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520346. Bookshelf ID: NBK84114. Diarsipkan dari versi asli tanggal 2020-10-26. Diakses tanggal 2023-04-30.
Bale BF, Doneen AL, Vigerust DJ (2018). "Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping". Frontiers in Cardiovascular Medicine. 5: 141. doi:10.3389/fcvm.2018.00141 . PMC 6198642 . PMID 30386783.

psychiatrictimes.com

Malhotra AK (2010). "The state of pharmacogenetics". Psychiatr Times. 27 (4): 38–41, 62. Diarsipkan dari versi asli tanggal 2012-08-25. Diakses tanggal 2023-04-30.

ugm.ac.id

"Farmakogenetik dan Farmakogenomik Mestinya Menjadi Paradigma Baru Dalam Terapi Obat". Universitas Gadjah Mada. 20 Agustus 2008. Diarsipkan dari versi asli tanggal 2023-05-10. Diakses tanggal 5 Maret 2023.

unc.edu

pharmacy.unc.edu

"Center for Pharmacogenomics and Individualized Therapy". Unc Eshelman School of Pharmacy. Diarsipkan dari versi asli tanggal 2015-07-02. Diakses tanggal 2014-06-25.

uptodate.com

"overview of pharmacogenomics". Up-to-Date. May 16, 2014. Diarsipkan dari versi asli tanggal 2011-11-19. Diakses tanggal 2014-06-25.

web.archive.org

"Center for Pharmacogenomics and Individualized Therapy". Unc Eshelman School of Pharmacy. Diarsipkan dari versi asli tanggal 2015-07-02. Diakses tanggal 2014-06-25.
"overview of pharmacogenomics". Up-to-Date. May 16, 2014. Diarsipkan dari versi asli tanggal 2011-11-19. Diakses tanggal 2014-06-25.
Holtzman, Neil A.; Marteau, Theresa M. (2000-07-13). "Will Genetics Revolutionize Medicine?". New England Journal of Medicine. 343 (2): 141–144. doi:10.1056/nejm200007133430213. ISSN 0028-4793. Diarsipkan dari versi asli tanggal 2023-07-18. Diakses tanggal 2023-03-04.
"Guidance for Industry Pharmacogenomic Data Submissions" (PDF). U.S. Food and Drug Administration. March 2005. Diarsipkan (PDF) dari versi asli tanggal 2016-10-06. Diakses tanggal 2008-08-27.
"Farmakogenetik dan Farmakogenomik Mestinya Menjadi Paradigma Baru Dalam Terapi Obat". Universitas Gadjah Mada. 20 Agustus 2008. Diarsipkan dari versi asli tanggal 2023-05-10. Diakses tanggal 5 Maret 2023.
"Clinical Pharmacogenetics Implementation Consortium". cpicpgx.org (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 2023-07-01. Diakses tanggal 2022-12-13.
U.S. Food and Drug Administration (FDA). "Table of Pharmacogenomic Biomarkers in Drug Labels". Food and Drug Administration. Diarsipkan dari versi asli tanggal 2017-08-22. Diakses tanggal 2014-09-03.
Malhotra AK (2010). "The state of pharmacogenetics". Psychiatr Times. 27 (4): 38–41, 62. Diarsipkan dari versi asli tanggal 2012-08-25. Diakses tanggal 2023-04-30.
Dean L (2012). "Clopidogrel Therapy and CYP2C19 Genotype". Dalam Pratt VM, McLeod HL, Rubinstein WS, et al. Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520346. Bookshelf ID: NBK84114. Diarsipkan dari versi asli tanggal 2020-10-26. Diakses tanggal 2023-04-30.

worldcat.org

Holtzman, Neil A.; Marteau, Theresa M. (2000-07-13). "Will Genetics Revolutionize Medicine?". New England Journal of Medicine. 343 (2): 141–144. doi:10.1056/nejm200007133430213. ISSN 0028-4793. Diarsipkan dari versi asli tanggal 2023-07-18. Diakses tanggal 2023-03-04.